<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <relatedBills />
    <recordedVotes />
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 161, Number 149 (Friday, October 9, 2015)]From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. VARGAS:H.R. 3731.Congress has the power to enact this legislation pursuantto the following:(1) to lay and collect taxes, duties, imposts and excises,to pay the debts and provide for the common defense andgeneral welfare of the United States; but all duties, impostsand excises shall be uniform throughout the United States, asenumerated in Article 1, Section 8, Clause 1 of the U.S.Constitution;(2) To borrow money on the credit of the United States, asenumerated in Article 1, Section 8, Clause 2 of the U.S.Constitution;(3) To regulate commerce with foreign nations, and amongthe several states, and with the Indian tribes, as enumeratedin Article 1, Section 8, Clause 3 of the U.S. Constitution;(4) To promote the progress of science and useful arts, bysecuring for limited times to authors and inventors theexclusive right to their respective writings and discoveriesas enumerated in Article 1, Section 8, Clause 8 of the U.S.Constitution;(5) to make all laws necessary and proper for executingpowers vested by the Constitution in the Government of theUnited States, as enumerated in Article I, Section 8, Clause18 of the United States Constitution.[Page H6974]</pre>]]></constitutionalAuthorityStatementText>
    <updateDate>2018-11-21T21:23:21Z</updateDate>
    <billNumber>3731</billNumber>
    <version>1.0.0</version>
    <titles>
      <item>
        <parentTitleType />
        <title>RaD Fund Act</title>
        <chamberName />
        <titleType>Short Titles as Introduced</titleType>
        <chamberCode />
      </item>
      <item>
        <parentTitleType />
        <title>Rare Disease Fund Act</title>
        <chamberName />
        <titleType>Short Titles as Introduced</titleType>
        <chamberCode />
      </item>
      <item>
        <parentTitleType />
        <title>To establish a Rare Disease Therapeutics Corporation to encourage the development of high-risk, high-return therapies for rare diseases, and for other purposes.</title>
        <chamberName />
        <titleType>Official Title as Introduced</titleType>
        <chamberCode />
      </item>
      <item>
        <parentTitleType />
        <title>RaD Fund Act</title>
        <chamberName />
        <titleType>Display Title</titleType>
        <chamberCode />
      </item>
    </titles>
    <title>RaD Fund Act</title>
    <latestAction>
      <text>Referred to the Subcommittee on Health.</text>
      <actionDate>2015-10-16</actionDate>
      <links />
    </latestAction>
    <amendments />
    <createDate>2015-10-10T08:54:51Z</createDate>
    <laws />
    <policyArea>
      <name>Health</name>
    </policyArea>
    <originChamber>House</originChamber>
    <calendarNumbers />
    <billType>HR</billType>
    <committees>
      <billCommittees>
        <item>
          <systemCode>hsif00</systemCode>
          <subcommittees>
            <item>
              <systemCode>hsif14</systemCode>
              <activities>
                <item>
                  <date>2015-10-16T21:49:17Z</date>
                  <name>Referred to</name>
                </item>
              </activities>
              <name>Health Subcommittee</name>
            </item>
          </subcommittees>
          <chamber>House</chamber>
          <activities>
            <item>
              <date>2015-10-09T13:01:20Z</date>
              <name>Referred to</name>
            </item>
          </activities>
          <name>Energy and Commerce Committee</name>
          <type>Standing</type>
        </item>
      </billCommittees>
    </committees>
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Advisory bodies</name>
          </item>
          <item>
            <name>Department of Health and Human Services</name>
          </item>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Drug therapy</name>
          </item>
          <item>
            <name>Health programs administration and funding</name>
          </item>
          <item>
            <name>Health technology, devices, supplies</name>
          </item>
          <item>
            <name>Medical research</name>
          </item>
          <item>
            <name>National Institutes of Health (NIH)</name>
          </item>
          <item>
            <name>Research administration and funding</name>
          </item>
          <item>
            <name>Research and development</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <actions>
      <actionTypeCounts>
        <introducedInTheHouse>1</introducedInTheHouse>
        <billReferrals>1</billReferrals>
        <placeholderTextForH>1</placeholderTextForH>
        <introducedInHouse>1</introducedInHouse>
      </actionTypeCounts>
      <item>
        <actionDate>2015-10-16</actionDate>
        <committee>
          <name>Health Subcommittee</name>
          <systemCode>hsif14</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <actionDate>2015-10-09</actionDate>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <type>IntroReferral</type>
        <links />
        <actionCode>H11100</actionCode>
      </item>
      <item>
        <text>Introduced in House</text>
        <actionDate>2015-10-09</actionDate>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <committee />
        <type>IntroReferral</type>
        <links />
        <actionCode>Intro-H</actionCode>
      </item>
      <item>
        <text>Introduced in House</text>
        <actionDate>2015-10-09</actionDate>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <committee />
        <type>IntroReferral</type>
        <links />
        <actionCode>1000</actionCode>
      </item>
      <actionByCounts>
        <houseOfRepresentatives>4</houseOfRepresentatives>
      </actionByCounts>
    </actions>
    <sponsors>
      <item>
        <middleName />
        <party>D</party>
        <lastName>Vargas</lastName>
        <state>CA</state>
        <fullName>Rep. Vargas, Juan [D-CA-51]</fullName>
        <byRequestType />
        <bioguideId>V000130</bioguideId>
        <firstName>Juan</firstName>
        <identifiers>
          <bioguideId>V000130</bioguideId>
          <lisID>2112</lisID>
          <gpoId />
        </identifiers>
        <district>51</district>
      </item>
    </sponsors>
    <congress>114</congress>
    <introducedDate>2015-10-09</introducedDate>
    <committeeReports />
    <notes />
    <summaries>
      <billSummaries>
        <item>
          <text><![CDATA[<p><b>Rare Disease Fund Act or the RaD Fund Act</b></p> <p>This bill requires the National Institutes of Health (NIH) to organize the Rare Disease Therapeutics Corporation to purchase rights to, fund the development of, and sell ownership interests in drugs, biological products, and medical devices for rare diseases.</p> <p>The NIH must sell stock in the corporation to investors as soon as practicable. The corporation and the NIH may enter into an agreement under which the NIH maintains an ownership interest in the corporation in exchange for providing the corporation with intellectual property or other assistance. The corporation is prohibited from paying dividends on its stock.</p> <p>The corporation must sell its interest in a rare disease therapy prior to the therapy entering large-scale clinical trials.</p> <p>The corporation must issue bonds guaranteed by the United States and may issue bonds backed by the corporation. For purposes of securities laws, the securities of the corporation are not issued or guaranteed by the federal government.</p> The bill establishes within the NIH the Rare Disease Therapeutics Corporation Science Advisory Council to advise the corporation on the purchase, sale, and development of rare disease therapies.]]></text>
          <updateDate>2015-10-09T04:00:00Z</updateDate>
          <name>Introduced in House</name>
          <versionCode>00</versionCode>
          <lastSummaryUpdateDate>2016-06-06T21:28:22Z</lastSummaryUpdateDate>
          <actionDesc>Introduced in House</actionDesc>
          <actionDate>2015-10-09</actionDate>
        </item>
      </billSummaries>
    </summaries>
    <cboCostEstimates />
    <cosponsors>
      <item>
        <party>R</party>
        <district>17</district>
        <firstName>Thomas</firstName>
        <sponsorshipWithdrawnDate />
        <bioguideId>R000583</bioguideId>
        <lastName>Rooney</lastName>
        <sponsorshipDate>2015-10-09</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <identifiers>
          <gpoId>7888</gpoId>
          <lisID>1916</lisID>
          <bioguideId>R000583</bioguideId>
        </identifiers>
        <middleName>J.</middleName>
        <fullName>Rep. Rooney, Thomas J. [R-FL-17]</fullName>
        <state>FL</state>
      </item>
    </cosponsors>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

